Ishita Drugs & Industries Ltd Stock Price Today (NSE: ISHITADR)

Ishita Drugs & Industries Ltd

74.372.63 (3.42%)
Market Closed

Fundamental Score

...

Ishita Drugs & Industries Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Ishita Drugs & Industries Ltd share price today is 74.37, down 3.42% on NSE/BSE as of 7 August 2026. Ishita Drugs & Industries Ltd (ISHITADR) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 21.83 (Cr). The 52-week high for ISHITADR share price is 90.85 and the 52-week low is 66.00. At a P/E ratio of 27.99x, ISHITADR is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 6.98% and a debt-to-equity ratio of 0.01.

Ishita Drugs & Industries Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
77.90
Low
68.10
Volume
368.2173913043478
Change
+1.03%

Ishita Drugs & Industries Ltd share price chart: 1.03% return over the past month. 52-week high ₹90.85, 52-week low ₹66.00.

Ishita Drugs & Industries Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
77.0078.6973.9174.371.23K (Cr)
77.0078.0077.0077.001.59K (Cr)
77.5077.5077.0077.001.23K (Cr)
73.2577.8073.2577.782.13K (Cr)
75.8077.5075.8077.113.66K (Cr)
74.8975.2774.5275.27458.00 (Cr)
75.6475.6475.2775.273.00 (Cr)
74.9074.9074.9074.900.00 (Cr)
74.8074.9074.8074.90363.00 (Cr)
74.0574.8074.0574.0651.00 (Cr)

Ishita Drugs & Industries Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
75.8078.6973.2574.37-1.89%
74.2077.9068.1075.27+1.44%
74.9085.0069.1174.11-1.05%
81.0287.3370.0074.90-7.55%
71.0085.6070.2981.02+14.11%
71.0089.4066.1269.11-2.66%
72.9875.8567.0070.97-2.75%
80.8989.0066.0068.38-15.47%
70.0090.8570.0080.00+14.29%
73.0074.8768.0270.00-4.11%
80.0081.2470.2573.00-8.75%
74.0087.9067.0081.40+10.00%

Returns & Performance

Poor

Return on Equity (ROE)

6.98%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

8.66%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

6.35%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Ishita Drugs & Industries Ltd Valuation Check

Good

Price to Earnings (P/E)

27.99x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

50.04%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-37.93%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-32.89%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

1.00%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-1.23%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

-1.23%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.01x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

19.00x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

0.37 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Ishita Drugs & Industries Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ISHITADR across key market metrics for learning purposes.

Positive Indicators

4 factors identified

Conservative Debt Levels (D/E: 0.01)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (19.00x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (50.04%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

8 factors identified

Below-Average Return on Equity (6.98%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (8.66%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Profit Decline Concern (-37.93%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Revenue Contraction (-32.89%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Growth History (1.00% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Earnings Growth (-1.23% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (-1.23% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Ishita Drugs & Industries Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Ishita Drugs & Industries Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
22.3/100
74
₹21.83
28.0
Average
6.98%
Poor
8.66%
Poor
0.0
Excellent
-1.23%
Poor
1.00%
Average
0.00%
66.4/100
1991
₹468821.49
37.7
Average
15.95%
Good
20.53%
Excellent
0.1
Excellent
16.75%
Excellent
11.78%
Good
0.82%
56.3/100
8056
₹193163.97
73.6
Average
16.53%
Good
21.96%
Excellent
0.0
Excellent
5.71%
Good
8.67%
Good
0.41%
51.4/100
5123
₹169902.02
77.5
Average
27.43%
Excellent
15.19%
Good
1.8
Average
12.07%
Good
11.80%
Good
0.76%
Cipla Ltd...
CIPLA500087
40.2/100
1473
₹116131.81
30.5
Average
11.60%
Average
15.49%
Good
0.0
Excellent
9.94%
Good
8.01%
Good
0.90%
74.1/100
1078
₹115375.77
21.3
Average
21.25%
Excellent
21.14%
Excellent
0.5
Excellent
18.77%
Excellent
12.45%
Good
0.09%
Lupin Ltd...
LUPIN500257
83.4/100
2415
₹113976.53
20.0
Average
28.68%
Excellent
29.93%
Excellent
0.3
Excellent
37.02%
Excellent
13.02%
Good
0.72%
61.5/100
2470
₹105053.91
52.3
Average
13.12%
Average
13.50%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%
41/100
1148
₹102660.46
25.6
Average
11.22%
Average
13.04%
Average
0.2
Excellent
15.44%
Excellent
12.09%
Good
0.65%
24.6/100
1580
₹90035.87
25.4
Average
10.06%
Average
12.80%
Average
0.2
Excellent
0.80%
Average
6.32%
Good
0.26%
34.1/100
1816
₹84016.75
93.9
Average
18.30%
Good
17.76%
Good
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%

Ishita Drugs & Industries Ltd PE Ratio History

Historical price-to-earnings ratio for ISHITADR — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20242.50₹92.4337x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Ishita Drugs & Industries Ltd Quarterly Performance

Latest quarterly metrics for ISHITADR — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-32.89%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-37.93%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

1.00%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

-1.23%

Compounded annual net profit growth over 5 years

Ishita Drugs & Industries Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for ISHITADR — calculated from daily price history

49RSI 14
Neutral — RSI 49

Momentum is balanced — neither overbought nor oversold.

SMA 50
75
▼ Price below SMA 50 — Short-term bearish
SMA 200
75
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
1K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Ishita Drugs & Industries Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Ishita Drugs & Industries Ltd (ISHITADR) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Ishita Drugs & Industries Ltd

About ISHITADR (Ishita Drugs & Industries Ltd)

Ishita Drugs & Industries Ltd is a dynamic force in the global pharmaceutical landscape, dedicated to the meticulous development and distribution of high-quality pharmaceutical ing...redients. Specializing in both established and innovative compounds, ISHITADR caters to the diverse needs of pharmaceutical manufacturers worldwide. Their state-of-the-art facilities adhere to stringent international regulatory standards, ensuring consistent product quality and safety. Driven by a commitment to scientific excellence and technological advancement, the company constantly invests in research and development to expand its product portfolio and offer cutting-edge solutions. ISHITADR strives to be a trusted partner, providing reliable and cost-effective ingredients that contribute to improved patient outcomes. The company's core expertise lies in the production of a broad spectrum of essential pharmaceutical materials. This includes vital active pharmaceutical ingredients for various therapeutic areas, alongside specialized fine chemicals crucial for drug formulation. Ishita Drugs & Industries excels in the synthesis of complex molecules and the purification of natural products. Beyond standard offerings, ISHITADR is adept at crafting tailored solutions. The company also takes pride in fostering collaborative relationships, working closely with clients to meet their specific requirements and offering customized product development services. Their dedication to flexibility and customer satisfaction positions them as a valuable asset within the pharmaceutical supply chain. ISHITADR's commitment extends beyond product excellence to encompass sustainable and responsible manufacturing practices. The company prioritizes environmental stewardship, employing eco-friendly processes and minimizing waste generation. With a global perspective, ISHITADR actively seeks opportunities to expand its market presence and forge strategic alliances. The company's unwavering focus on quality, innovation, and customer service makes it a preferred supplier for pharmaceutical manufacturers seeking reliable and trustworthy partners. By consistently delivering high-quality products and adapting to evolving market demands, Ishita Drugs & Industries Ltd remains a prominent player in the pharmaceutical ingredients industry.

Company Details

Symbol:ISHITADR
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Jagdishprasad Gokulchand Agrawal
Chairman & MD
Mr. Sumit J. Agrawal
Chief Financial Officer
Mr. Kiran Rindani
Head of Operations

ISHITADR Share Price: Frequently Asked Questions

What is the current share price of Ishita Drugs & Industries Ltd?

Ishita Drugs & Industries Ltd (ISHITADR) trades at ₹74.37 on NSE and BSE. Market cap ₹21.83 (Cr). Educational data only.

What is the P/E ratio of Ishita Drugs & Industries Ltd?

Ishita Drugs & Industries Ltd has a P/E of 27.99x vs industry average 34.89x.

What is the Bull Run score for Ishita Drugs & Industries Ltd?

Ishita Drugs & Industries Ltd has a Bull Run score of 22.3/100 based on 25+ financial parameters.

Does Ishita Drugs & Industries Ltd pay dividends?

Ishita Drugs & Industries Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Ishita Drugs & Industries Ltd?

Ishita Drugs & Industries Ltd has ROE of 6.98%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Ishita Drugs & Industries Ltd?

Ishita Drugs & Industries Ltd has debt-to-equity of 0.01.

Is Ishita Drugs & Industries Ltd a good investment?

Bull Run gives Ishita Drugs & Industries Ltd a score of 22.3/100. This is not investment advice — consult a SEBI-registered advisor.